Conventional follow-up
ProcedurePatients in this group benefit from conventional post-operative follow-up
NCT Number: NCT04369118
The objective of this study is to evaluate the efficacy of a new medical device in post-surgery of lung resection. The principle of this new device is based on selective chest wall restriction. This new modality of chest wall restriction is evaluated on patients in post-surgery for lung cancer.
The hypothesis is that the use of this medical device would reduce the postoperative pain and increase the efficacy of cough and expectoration. The evolution of the operated patient would be better.
Looking for future studies?
Notify Me18 year–79 year
All sexes
Interventional
Not applicable
Assistance Publique Hôpitaux de Paris, Hôpital Avicenne, Bobigny, France
The present study is the first evaluation of the efficacy of a selective chest wall restriction belt.
The efficacy will be estimate on forced expiratory volume in one second (FEV1) at D3 by comparing 2 groups: a control group of patients with conventional follow-up and an experimental group of patients with conventional follow-up and a daily wear of the selective chest wall restriction belt after surgery.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Patients in this group benefit from conventional post-operative follow-up
Patients in this group benefit from conventional post-operative follow-up. The patient wear the selective chest wall restriction belt from Day 2 (after surgery) until he ceases to need it.
Time frame: 3 days
Comparisons of forced expiratory volume in one second (FEV1) between the two groups at Day 3. The value of FEV1 is standardized with pre-operative one.
Time frame: 1 month
Comparisons of pulmonary function test ( forced expiratory volume in one second (FEV1), Forced vital capacity (FVC)) between the two groups. They are expressed as Liters. Before surgery, all days from Day 2 to the patient's exit from hospital (max Day 6) and at the follow-up visit at Month 1. Each value is standardized with pre-operative one.
Time frame: 1 month
Comparisons of Peak expiratory flow at cough (PEF) between the two groups. It is expressed as Liters per second. Before surgery, all days from Day 2 to Day 6 and at the follow-up visit at Month 1. Each value is standardized with pre-operative one.
Time frame: 1 month
The patient pain is evaluated using the ENS (Echelle Numérique Standard; standard digital scale, score between 0 to 10) for the two groups. The pain is evaluated all days from Day 2 to the patient's exit from hospital, at the weekly phone follow-up until Month 1 and at the follow-up visit at Month 1.
Time frame: 10 days
The cough is classified with this scale : 0-dry cough; 1-productive cough without expectoration; 2-productive cough with expectoration; 3-productive cough with important and/or difficult expectoration. It's qualified for the two groups all days from Day 2 to the patient's exit from hospital.
Time frame: 1 month
The analgesic drugs are characterized by their class, dose and number of dose taken in the two groups. These elements are evaluated all days from Day 2 to the patient's exit from hospital, at the weekly phone follow-up until Month 1 and at the follow-up visit at Month 1.
Time frame: 1 month
Use of aerosol therapy (yes/no) and class of drugs. Use of antibiotic therapy (yes/no), type of drugs and expected duration of treatment. Use of loco-regional anaesthesia (yes/no), modality of administration and type of drugs. These elements are evaluated all days from Day 2 to the patient's exit from hospital, at the weekly phone follow-up until Month 1 and at the follow-up visit at Month 1.
Time frame: 1 month
Number and classification of post-surgery complications.For the two groups from Day 1 to the follow-up visit at Month 1.
Time frame: 10 days
The length of hospital stay in days for the two groups.
Time frame: 1 month
The EQ-5D is a generic preference-based measure that indirectly measures the utility for health that generates an index-based summary score based upon societal preference weights. The EQ-5D-5L consists of 6 items that cover 5 main domains (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and a general visual analog scale (VAS) for health status. Each item has 5 response levels ranging from level 1 (no problem or none) to level 5 (unable to perform activity). The VAS ranges from 0 (worst health status) and 100 (best health status). Comparison between the two groups preoperatively, at the patient's exit from hospital, at Day 15 during the phone follow-up and at the follow-up visit at Month 1.
Time frame: 1 month
Comparions of the number of the consumption of hospital care (medical acts and consultations, rehospitalization) between the two groups from Day 1 to the follow-up visit at Month 1.
Time frame: 1 month
Only for the medical device's group.
Time frame: 1 month
Only for the medical device's group. This questionnaire uses Likert scales from 0 to 10 to evaluate each use step ofthe medical device, closed-ended questions and open questions fr comments. It will be asked at the end of the clinical study at each caregiver.
University Hospital, Grenoble
Other
Efficacy Study of a Selective Chest Wall Restriction Belt in Postoperative of Lung Resection. A Multicenter, Prospective, Controlled, Randomized Study With Stratification on the Surgical Approach, Open With a Blind Analysis
Acronym: CTS-POP
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00365105
Breast Cancer, Breast Diseases
Mobile, Alabama, United States
View Trial DetailsNCT00303914
Breast Cancer, Breast Diseases
Chicago, Illinois, United States
View Trial DetailsNCT03649737
Behavior, Behavioral Symptoms
Portland, Oregon, United States
View Trial DetailsNCT02063438
Hernia, Lung Cancer
Ann Arbor, Michigan, United States
View Trial Details